A Phase 1 Randomized Double-Blind Positive-Controlled Ascending Dose Study to Evaluate the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4 Anthrax Vector Candidate Vaccines - Ad4-PA (Protective Antigen)and Ad4-PA-GPI (Glycosylphosphatidylinositol)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2014
At a glance
- Drugs Anthrax vaccine (Primary)
- Indications Anthrax
- Focus Adverse reactions
- Sponsors PaxVax
- 25 Jul 2014 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 25 Jul 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
- 25 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.